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Abstract
In addition to the classic motor symptoms, Parkinson’s disease (PD) is associated with a variety of 
non-motor symptoms that significantly reduce quality of life, even in the early stages of the 
disease. There is an urgent need to develop evidence-based treatments for these symptoms, which 
include mood disturbances, cognitive dysfunction, and sleep disruption. We focus here on exercise 
interventions, which have been used to improve mood, cognition, and sleep in healthy older adults 
and clinical populations, but to date have primarily targeted motor symptoms in PD. We 
synthesize the existing literature on the benefits of aerobic exercise and strength training on mood, 
sleep, and cognition as demonstrated in healthy older adults and adults with PD, and suggest that 
these types of exercise offer a feasible and promising adjunct treatment for mood, cognition, and 
sleep difficulties in PD. Across stages of the disease, exercise interventions represent a treatment 
strategy with the unique ability to improve a range of non-motor symptoms while also alleviating 
the classic motor symptoms of the disease. Future research in PD should include non-motor 
outcomes in exercise trials with the goal of developing evidence-based exercise interventions as a 
safe, broad-spectrum treatment approach to improve mood, cognition, and sleep for individuals 
with PD.
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Although traditionally conceptualized as a motor disorder, Parkinson’s disease (PD) is also 
associated with a variety of non-motor symptoms. These symptoms – including disturbances 
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of mood, cognition, and sleep – substantially reduce quality of life, often to a greater extent 
than the motor symptoms.1–4 Also of note, traditional dopaminergic treatments for PD may 
exacerbate or contribute, at least in part, to mood, cognitive, and especially sleep symptoms 
in this population.5 In this article, we present the evidence supporting aerobic exercise and 
strength training as promising broad-spectrum interventions for these specific non-motor 
symptoms in PD, beyond the well-established benefits for core motor symptoms. To date, 
most exercise programs in PD have focused on improving physical function, including gait, 
mobility, and balance, and on targeting disease-specific physical impairments, such as 
bradykinesia, rigidity, and strength.6–8 In general, exercise, including aerobic and resistance 
training, improves physical function and motor symptoms in PD.9–19 Given these benefits to 
core symptoms, exercise has a potential to be one of those rare adjunct interventions to treat 
principal non-motor symptoms of PD without worsening the primary motor disorder.
In this manuscript, we review the efficacy of aerobic and strengthening exercise 
interventions in PD relative to more conventional treatments of mood, cognition, and sleep. 
The following electronic databases were searched: PubMed (1990 to July 6th 2015), Google 
Scholar (1990 to July 6th 2015), and Cochrane Library (1990 to July 6th 2015); citation 
tracking was also used to identify relevant references. Specifically, we included studies if 
they met the following criteria: 1) at least one target population was adults with PD; 2) 
aerobic exercise and/or resistance exercise was used in at least one of the exercise 
conditions; 3) at least one outcome measure was included to examine mood (depression or 
anxiety), cognition, or sleep; 4) the paper was available in English as of July 6, 2015. To 
inform these findings, we also discuss the relevant literature on aerobic and resistance 
exercise in healthy older adults, as well as neurologic populations. Although many forms of 
exercise may be beneficial, we limited our review to studies that included aerobic and/or 
strengthening exercise, as the evidence in these areas is more developed in healthy older 
adults and in persons with PD from both a clinical and mechanistic perspective. Also of 
note, additional non-motor symptoms manifest in PD, including fatigue and autonomic, 
gastrointestinal, and sensory symptoms,20 but the literature investigating the effects of 
exercise on these symptoms remains very limited; accordingly, the present article focuses on 
the potential benefits of exercise interventions on mood, cognition and sleep only.
Treatment of Mood Symptoms in PD
Mood disturbance (here referring to depression and anxiety) develops in many individuals 
with PD, even in the early stages of the disease,21 contributing to poorer quality of life1,2,22 
and caregiver burden.23 Major depression is estimated to occur in 20–40% of individuals 
with PD,24,25 and clinically significant anxiety in approximately 40%26–28 (prevalence of 
psychiatric symptoms in PD reviewed in 22). Depression in PD is associated with poorer 
emotional well-being, communication, and activities of daily living,29,30 as well as increased 
disability, falls, and caregiver distress, with some research indicating that depression may 
predict 10-year mortality.31–33 Despite these high prevalence rates and associated distress 
and disability, clinical management of many non-motor symptoms, including depression and 
anxiety, remains inadequate.34
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Anxiety is common but less studied and treated in PD than depression.34–37 In addition to 
generalized anxiety disorder, panic disorder, and simple and social phobias, individuals with 
PD also report recurrent situational anxiety related to their motor symptoms, including fear 
of falling or fear of crowded places due to freezing of gait.27,28 Anxiety is associated with 
reduced quality of life in PD,38–40 even after controlling for the effects of motor 
symptoms,3,41 and to a greater extent than depression.2
The high prevalence, early manifestation, and negative impact of anxiety and depression in 
PD dictate the need to manage and improve these symptoms, which are under-treated and 
understudied.42–46 To date, antidepressants have generally yielded non-significant and 
variable effects for both depression46,47 and anxiety46 in PD. Some controlled studies 
suggest that certain selective serotonin reuptake inhibitors, dual reuptake inhibitors, and 
dopamine agonists may improve depression in PD, albeit with some risk of treatment-related 
side effects (e.g. fatigue, dry mouth, orthostatic hypotension, dyskinesia).48–50 
Benzodiazepines are not recommended for the treatment of anxiety in PD due to potential 
side effects, including autonomic, cognitive, sleep, and psychomotor impairments.22,51,52 
There is emerging evidence for psychosocial alternatives to pharmacologic treatment of 
mood, with limited but promising data from cognitive behavioral therapy (CBT).46,53–60
The Potential of Exercise Interventions for Mood
Exercise interventions have demonstrated robust efficacy in the treatment of mood 
symptoms in the general population and in older adults, but few exercise trials in PD have 
included mood as an outcome measure. A meta-analysis of 11 randomized control trials 
(RCTs) with adults with major depression reported a large combined effect size for exercise, 
usually aerobic or resistance training, relative to non-active control conditions.61 More 
recent meta-analyses confirm a significant acute effect of exercise on depression relative to 
non-exercising control groups,62 with benefits generally following programs of at least 
moderate aerobic activity delivered several times a week, often in a group setting, with 
session durations of 20 to 45 minutes.61 Although promising, these meta-analyses are not 
without limitations, such as restricted power due to the small number of included trials, as 
well as the selection bias of individuals who volunteer to participate in exercise 
research.61,62 Despite this, the benefits of exercise are conferred across a wide range of 
settings and symptom severities. For example, Mota-Pereira and colleagues63 found that 
aerobic exercise (30–45 minute sessions, 5 days/week) offered significant improvement or 
remission of depression in outpatients who had failed two previous trials of antidepressant 
medication (see also 64). Aerobic exercise also has efficacy in combination with 
antidepressants or CBT.65,66 Even in healthy adults without clinical depression, exercise 
interventions, including resistance exercise, have improved depressive symptoms.67 In sum, 
exercise has been shown to reduce depression in the general population, suggesting that it 
may also benefit those with PD and depression, either as a stand-alone or adjunctive 
intervention to improve mood.
Besides its antidepressant effects, exercise is also anxiolytic.68,69 Strong effects on self-
reported anxiety were documented in a meta-analysis of primarily non-clinical samples70 
with further evidence from clinical trials for panic disorder, generalized anxiety disorder, 
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and social anxiety.68 These clinical trials have focused largely on aerobic exercise (usually 
completed 2–5 times per week, for 5–12 weeks), often in small samples, with 
unstandardized or unsupervised exercise sessions and/or lacking a non-exercising control 
group; nevertheless, the results are encouraging and suggest that aerobic exercise, in 
particular, may effectively treat anxiety disorders, either as a stand-alone intervention or as 
an adjunct treatment in combination with pharmacotherapy or CBT.68,71 More controlled 
studies are needed to determine the optimal exercise dose and modality required to achieve 
lasting anxiolytic effects.
Exercise has also been shown to improve mood in healthy older adults (e.g. 72). For 
example, physical exercise, usually aerobic or resistance training completed 3 times per 
week for 20–60 minutes for 6–19 weeks, yielded positive short-term outcomes for 
depressive symptoms;73,74 and compared to a non-exercising control group, aerobic (but not 
resistance) exercise was associated with reduced depressive symptoms, regardless of 
baseline level of depression.75 Comparing an aerobic exercise program to pharmacological 
treatment, exercise (three 45-minute sessions/week) was equally effective at reducing 
depressive symptoms after 16 weeks of treatment, although the study did not control for the 
social interaction aspect of the exercise group.76
There is promising evidence that exercise may improve depression among adults with 
neurologic disorders,77 but there remains limited research on the effects of aerobic and 
resistance exercise on mood in PD specifically. In a large RCT with 231 adults with PD, six 
months of strengthening exercises (40–60 minutes, 3 times/week) yielded improved positive 
affect relative to a usual-care control group.18 In a second controlled trial, individuals with 
PD were randomized to either an early- or late-start group exercise program (combined 
cardiovascular and strength training, completed for 60 minutes, 3 days/week, for 24–48 
weeks).78 Participants in the early-start group reported significantly fewer depressive 
symptoms after 48 weeks, relative to the delayed start group, although there was no control 
for the potential effects of weekly social interaction on mood. In a comparative trial of three 
types of exercise (high-intensity treadmill training, lower-intensity treadmill training, and 
stretching/resistance training), no changes in depression were observed for any group after 3 
months of exercise (30–50 minutes, 3 times per week), although participants reported only 
mild levels of depressive symptoms at baseline.79 In a smaller study, aerobic exercise, 
completed twice per week for 12 weeks, improved mood, while maintaining functional 
ability, among 13 adults with early PD relative to non-exercising PD participants.80 In a 
sample of 11 early- to mid-stage participants with PD, 5 participants (mean age=64.0) 
completed a 4-week general exercise program (60-minute sessions of combined aerobic and 
resistance training, 4 times/week), and 6 participants (mean age=62.8) completed an 
exercise-based behavioral treatment focused on increasing amplitude of movement.81 
Although there were no between group differences, the combined group showed 
improvement in depression and fatigue at all post-intervention assessments (weeks 4, 12, 
24), suggesting benefits of both exercise approaches. In an uncontrolled trial, 49 individuals 
with PD (mean age=65.5) reported reduced depressive symptoms after six months of aerobic 
walking (3 times/week for 45 minutes per session), although depressive symptoms were 
very low among this sample.82 In general, the PD exercise studies that have included mood 
outcomes have included participants with minimal depressive symptoms, limiting their 
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generalizability. Even so, these studies provide strong rationale for the targeted use of 
exercise to improve mood in PD.
Cognitive Impairment in PD
Like mood symptoms, cognitive impairments are common and heterogeneous in PD,83–87 
even in the early stages of the disease, with widespread implications for quality of life and 
functional abilities such as driving.1,88–93 Cognitive disruptions can also co-occur with other 
non-motor symptoms, tending to be worse in PD with depression, for example.94,95 Up to 
57% of individuals with PD experience some cognitive impairment within the first 3–5 years 
after diagnosis,96 including deficits in executive functioning, visuospatial function, and 
attention/working memory.97–99 Measures of attention and executive function (“frontal” 
tests) are often the most sensitive to cognitive compromise.100 Executive dysfunction often 
emerges early in the disease course and is thought to be associated with dopaminergic 
dysfunction in fronto-striatal regions, whereas memory impairment and visuoconstructional 
difficulties, along with cognitive decline and dementia, may be driven by cortical Lewy 
body pathology and cholinergic deficiency.87,88,96,101,102,103 With cognitive impairment 
beginning in the early stages of PD,88 there is a corresponding need for early cognitive-
enhancement strategies.
The Potential of Exercise Interventions for Cognitive Enhancement
There is reliable evidence for significant benefits conferred upon cognition by exercise 
programs.104,105 A meta-analysis of RCTs (29 studies, 2049 participants) has indicated that 
healthy older adults reliably achieve modest improvements in attention and processing 
speed, executive function, and memory following aerobic training.105 The exercise trials 
ranged in duration from 6 weeks to 18 months, with modal length of 2.5 to 4 months, but 
with relatively minimal range of exercise intensity or frequency across trials (most often 3 
times per week at 70% peak oxygen uptake (VO2)). Exercise typically comprised brisk 
walking and/or jogging relative to wait-list control or other comparison conditions 
(stretching and toning, health education, or relaxation). Greater benefits to attention and 
processing speed arose from trials that combined aerobic exercise with strength training, 
relative to aerobic only interventions. Likewise, aerobic training has been reported to 
improve cognition in healthy older adults, especially for executive-control processes106 – a 
finding particularly pertinent to the goal of improving executive dysfunction in PD.97,100 
There remains need for additional research to examine how aerobic exercise may affect 
various cognitive domains when maintained for extended periods of time (e.g. several years 
instead of months).105
Exercise may also improve general cognitive functioning and balance in older-adult 
neurological populations, including those with mild cognitive impairment, as well as 
Alzheimer’s disease (AD) and other dementia-causing disorders.107,108 This research is 
relevant to PD, given that cognitive impairment, including dementia, often emerges over the 
course of the disease109–111 and that an AD-like pattern of brain atrophy in PD may predict 
cognitive decline.112 There is preliminary evidence that aerobic exercise may be associated 
with greater memory improvements among adults with mild cognitive impairment relative to 
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cognitively intact adults.105 In a large sample of adults (≥ 50 years) with subjective memory 
impairment, a six-month exercise program (at least three 50-minute sessions of moderate-
intensity aerobic exercise per week) yielded modest improvements on brief cognitive tests of 
memory, language, and praxis (Alzheimer Disease Assessment Scale – ADAS-Cog) over an 
18-month follow-up period; participants in the exercise group also improved on word list 
delayed recall.113 It is important to note that the primary outcome measure in this study was 
a non-specific measure of overall cognitive function, rather than an index of a specific 
cognitive domain. Relative to a non-active control group, elderly individuals with AD (mean 
age=78.3) demonstrated improved balance and executive functioning (Clock Drawing Test 
and Frontal Assessment Battery) following dual-task exercise that paired motor and 
cognitive tasks (60-minute sessions completed 3 times/week for 4 months).114 Aerobic 
training has also been reported to improve visual learning, working memory, and processing 
speed in psychiatric populations, including depression.115 In sum, exercise has demonstrated 
cognitive benefits in healthy older adults and in adults with conditions that may be observed 
in PD (e.g. depression and dementia), supporting the potential cognition-enhancing role of 
exercise for PD.
There is initial evidence that these expectations will be realized in PD.116,117 Aerobic 
exercise may particularly impact executive function in PD,118 consistent with the findings in 
healthy older adults.106 Twelve weeks of combined aerobic plus anabolic exercise, 
conducted twice weekly, resulted in selective improvement in frontal-based executive 
function (spatial working memory and verbal fluency, relative to spatial and pattern 
recognition memory) in 15 individuals with PD compared to 13 non-exercising PD control 
participants (all in mild to moderate disease stages and approximately 60 years old).119 
Likewise, in relatively large studies of a long duration, 6 months of moderate-intensity 
aerobic exercise, conducted three times per week for 45–60 minutes, led to improved 
executive functioning for individuals with mild to moderate PD (mean age of approximately 
65 in both studies), though only one of these studies used a non-exercising PD control 
group.82,120 Across these studies, moderate-intensity aerobic exercise, conducted 2–3 times 
per week, produced promising effects on executive function in the mild to moderate stages 
of PD, consistent with studies in healthy older adults.106 In small preliminary case studies, 8 
weeks of aerobic exercise, completed 3 times per week for 20–40 minutes, yielded 
improvements in executive function, verbal fluency, and working memory for three 
individuals with PD – one with high cognitive performance at baseline (age 66), and two 
with cognitive impairments (ages 61 and 72).121,122 Further research is warranted to 
examine the underlying mechanisms driving these selective improvements, which may relate 
to increased cerebral perfusion, release of growth factors, or angiogenesis following aerobic 
exercise, as suggested by Tabak and colleagues.121 Among healthy older adults, aerobic 
training, relative to non-aerobic, may even mitigate volume loss in prefrontal regions,123 
which are associated with a variety of executive control processes. Of note, both prefrontal 
atrophy and executive dysfunction occur in PD, even in the early stages of the disease.97,124
At the same time, recent evidence suggests that resistance exercise may also benefit 
cognition in PD. After 24 months of twice weekly progressive resistance exercise (60–90 
minutes per session), adults with PD improved their performance on measures of working 
memory, inhibition, and attention (Digit Span, Stroop, Brief Test of Attention).125 The 
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comparison group completed stretching, balance, and non-progressive strengthening 
exercises (of the same duration and frequency) and improved on Digit Span and Stroop after 
24 months.125 There were no between-group differences on any of the cognitive measures at 
12 or 24 months, and the authors noted that their sample was relatively young, highly 
educated, and in mild-to moderate disease stages, thereby limiting the generalizability of 
their findings.125 Even so, these results provide clear rationale for future research to 
examine the targeted use of resistance exercise to improve cognition in PD. Taken together, 
emerging research suggests that aerobic and resistance exercise may improve cognition in 
PD; however, there remains a need for larger, well-controlled studies on the cognitive 
effects of exercise interventions among adults with PD.
Sleep Disruption in PD
In the general population, the prevalence of insomnia symptoms ranges from 25% to 48% 
and insomnia diagnoses from 4.4% to 9.5%.126–129 Sleep disruptions are common among 
older adults130 and are particularly problematic and multifactorial in PD,40,131,132 with 
reference to this problem dating back to James Parkinson’s observations in his original 
essay.133 Fragmented sleep has been reported,134–139 attributed in part to nighttime motor 
symptoms,140,141 with reports of sleep benefits upon control of these symptoms.142,143 
Individuals with PD may present with REM sleep behavior disorder, excessive daytime 
sleepiness, sleep onset and sleep maintenance insomnia, as well as sleep disordered 
breathing, restless leg syndrome, and nocturia.132,144 Furthermore, sleep disturbances in PD 
are linked to mood and cognitive dysfunction,145–147 likely related to neurodegenerative 
changes. The underlying disease pathology in PD is now thought to begin in the 
brainstem,148 where damage to specific nuclei (e.g., locus ceruleus, pedunculopontine 
nucleus) and neurotransmitters (e.g., norepinephrine, serotonin, dopamine, GABA, 
acetylcholine) likely affects sleep-wake and REM sleep modulation in PD years prior to the 
manifestation of motor symptoms.132,140,144,149 Given the magnitude of the impact of sleep 
disruption on quality of life in PD,1,150 there is need to address general, age-related, and 
disease-specific sleep disruptions in those with PD.
The Potential of Exercise Interventions for Sleep Disruption
Meta-analytic review of 25 studies indicates that regular exercise programs help adults 
achieve moderate-to-large sleep quality benefits, as per the self-reported Pittsburgh Sleep 
Quality Index (PSQI),151 which includes subscales of daytime sleepiness as well as sleep 
disturbance, duration, efficiency, latency, and medication use.152 The moderate-to-large 
effects of regular exercise were observed for all PSQI subscales except sleep medication 
use. Across aerobic, anaerobic, and mixed studies, regular exercise had small effects on total 
sleep time and sleep efficiency and a small-to-moderate effect on sleep onset latency, 
predominantly assessed using objective measures (e.g. electroencephalogram or 
polysomnography).152 These benefits appear to be uniform across younger and older 
samples except for weaker effects on sleep-onset latency in older adults, consistent with its 
general worsening with age.127 Even individual sessions of exercise, evaluated across 41 
studies (predominantly aerobic training), conferred benefit on objective measures of sleep, 
though with small effect sizes that varied in reliability.152 Moderate-intensity aerobic 
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exercise (30- to 40-minute sessions, completed four times per week, for 16 weeks) yielded 
improvements in self-reported sleep quality (global PSQI score) among healthy older adults 
(ages 50–76) with sleep complaints, relative to wait-list control participants.153
There is some indication that the benefits of exercise for sleep extend to individuals with 
PD, including improved sleep, quality of life, and daily functioning.154,155 In an RCT (with 
stratified randomization), 17 PD participants in mild to moderate stages (mean age=67.8) 
who completed six months of multimodal exercise (three 60-minute sessions per week of 
muscular resistance, balance/motor coordination, and aerobic fitness) reported enhanced 
sleep and functional abilities on standardized questionnaires compared to 17 PD control 
participants who did not exercise.155 The sleep questionnaire (Mini-Sleep Questionnaire) 
included items related to both insomnia and daytime sleepiness. Only the total score was 
used for data analysis, so it is not possible to determine if exercise more strongly affected 
insomnia or daytime sleepiness. Likewise, after 36 group sessions of combined aerobic 
conditioning and muscular strengthening (75 minutes each, 3 times per week, for 3 months), 
twenty mild- to moderate- stage PD participants (mean age=61.5) reported significant 
improvements in quality of life, particularly within the domains of emotional reactions, 
social interactions, and physical ability, as well as reporting a trend toward improved sleep 
on a self-report questionnaire.154 A significant limitation of both PD studies was the lack of 
objective sleep measures. Further research is needed to elucidate potential effects of exercise 
on daytime and nighttime sleep disturbances, including larger, well-controlled trials that 
include subjective and objective sleep outcome measures.
Potential Mechanisms of Action of Exercise on Mood, Cognition, and Sleep
Dopaminergic dysfunction in the hypothalamus and limbic regions may be associated with 
disturbances of mood, cognition, and sleep in PD.156–159 It is plausible then that exercise 
may improve these non-motor symptoms at least partially via dopaminergic mechanisms. 
More specifically, exercise may modulate dopaminergic and glutamatergic 
neurotransmission, and thereby attenuate basal ganglia hyperexcitability in PD.160,161 
Among exercising rats (n=10) relative to sedentary counterparts (n=9), aerobic exercise (6 
weeks of wheel running) has been associated with increased dopamine synthesis and 
reduced inhibition of dopamine neurons in the substantia nigra pars compacta.162 
Preliminary evidence in humans suggests that aerobic exercise (three 60-minute treadmill 
sessions/week for 8 weeks) may lead to increased dopaminergic signaling (per imaging with 
positron emission tomography) and improved postural control in the early stages of PD.163 
Although non-motor outcomes were not included in this pilot study, the reported 
improvements in postural control are potentially relevant for non-motor symptoms given 
that common neural substrates may modulate balance control and anxiety (e.g. parabrachial 
nucleus network and associated connections to limbic regions).156,164,165
Besides its dopaminergic effects, regular exercise also has a wide variety of effects on non-
dopaminergic neurotransmitter systems, including serotonergic, noradrenergic, and GABA-
ergic systems, which is relevant for depression, anxiety, and sleep.166,167 In rats that swam 
(n=18) 5 days a week for 10 weeks (typically 30 minutes per day), exercise was associated 
with increased hippocampal levels of serotonin and norepinephrine168 – two 
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neurotransmitters that have been implicated in modulation of anxiety, depression, and 
sleep.156,169–171 In regard to the potential for improved cognition,172 animal work indicates 
that serotonin is necessary in order to achieve exercise-induced neurogenesis in the 
hippocampus (n=30 per group).173 In human research, aerobic exercise (three 30-minute 
cycling sessions per week, for 7 weeks) has been associated with reduced depression and 
reduced blood serotonin, relative to a stretching-control group.174 This effect is similar to 
effects of selective serotonin reuptake inhibitors, although the sample consisted of healthy 
undergraduate students who were not pre-screened for anxiety or depression, which limits its 
generalizability. These findings suggest that aerobic exercise may increase levels of 
serotonin and norepinephrine in the brain, which may positively affect mood, cognition, and 
sleep. For example, cognitive dysfunction and sleep disturbances (e.g. insomnia, vivid 
dreaming, and sleep-disordered breathing) in PD are generally unresponsive to dopamine 
therapy,175 suggesting that these symptoms may develop, at least in part, through non-
dopaminergic mechanisms. Likewise, anxiety in PD is associated with dysfunction in a 
variety of neurotransmitter systems, including noradrenergic and serotonergic, which may 
precede dopaminergic depletion.156 Aerobic exercise, then, could act upon these non-
dopaminergic systems to improve non-motor symptoms, particularly in the early stages of 
PD.
The mechanisms by which exercise may affect non-motor symptoms, especially cognition, 
in PD may be similar to structural and functional brain changes and proliferation of growth 
factors seen in exercising healthy adults. Higher aerobic fitness in healthy older adults 
(mean age=66.6) has been associated with greater gray matter volume in dorsolateral 
prefrontal cortex and improved executive function (Stroop test of inhibition) and spatial 
working memory.176 The association with prefrontal volume is relevant to PD as affected 
individuals may show prefrontal and hippocampal atrophy even in early stages of the 
disease.124 Imaging with positron emission tomography has also revealed that prefrontal 
dysfunction in PD (hypometabolism) contributes to difficulties with set-shifting.177 
Following a one-year walking intervention (three 40-minute sessions per week), aerobic 
fitness in older adults was associated with white matter changes in frontal and temporal 
regions, as well as improved short-term memory relative to an active control group 
(flexibility, toning, and balance).178 Also following one year of aerobic exercise, increased 
functional connectivity in the temporal lobe among healthy older adults (mean age=66.4) 
was associated with increased levels of growth factors, including brain-derived neurotrophic 
factor (BDNF), as well as insulin-like growth factor type 1, and vascular endothelial growth 
factor.179 Consistent with these findings, regular aerobic exercise in healthy older adults is 
thought to promote neuroplasticity and facilitate learning and memory through the release of 
neurotrophins, including BDNF, glia-derived neurotrophin (GDNF), nerve growth factor 
(NGF), and galanin.106,180 In PD, aerobic exercise may increase the production of growth 
factors and promote gray and white matter changes, especially in prefrontal regions, both of 
which may contribute to improved cognitive function.
Animal and cellular studies further highlight the important effects of BDNF on 
neurogenesis, dendritic growth, and long-term potentiation.181–184 Meta-analytic review of 
29 human studies (1111 participants) indicates that single sessions of exercise induce BDNF 
activity and that there is a significant increase in this activity with regular exercise.185 These 
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effects appear reliable enough that Szuhany and colleagues185 suggested that exercise can be 
considered as an intervention to induce BDNF for subsequent therapeutic benefit, although 
they note that future research is needed to examine the effects of exercise type (e.g. aerobic 
versus resistance training) on BDNF. Rodent and human studies indicate that BDNF may 
mediate both the mood and cognitive effects of exercise,186–189 with a particular effect on 
executive function in older adults,190 which is known to be compromised in PD.97
These mechanisms may relate to potential cognitive benefits of exercise in PD, given the 
known executive dysfunction and reduced BDNF expression in this population. Postmortem 
human studies and rodent studies indicate significantly reduced expression of BDNF in the 
substantia nigra in PD,191–194 and surviving dopaminergic neurons in the substantia nigra 
express reduced BDNF compared to control cases.192 In a 6-hydroxydopamine (6-OHDA) 
rat model of PD, exercise (4 weeks of treadmill running, 30 minutes/day, 5 days/week) has 
been found to increase levels of BDNF in the striatum.195 In a recent human study of early-
stage PD, 28 days of intensive aerobic exercise increased BDNF levels, improved motor 
symptoms (balance and gait),196 and potentially slowed motor symptom progression after a 
two-year follow-up.197 Indeed, drawing largely from animal studies, Fumagalli and 
colleagues198 posited that BDNF may function as a neuroprotective molecule and also a 
neuromodulator in PD, such that it is associated with the loss of dopaminergic neurons when 
inhibited, and with improved cognition when expressed. Exercise may improve hippocampal 
function via BDNF expression,199 and in non-PD rats (n=7 per group), BDNF expression 
has been associated with exercise-induced enhancement on learning and recall on the Morris 
water maze after one week of voluntary wheel running.189 Though there are limitations 
related to translating results in animal models of PD to humans with PD,200 animal work as 
well as emerging human research suggest that aerobic exercise may lead to improvements in 
cognition that may be mediated, at least in part, by increased production of BDNF.201 In 
sum, the potential effects of exercise-induced BDNF on cognition in PD are particularly 
promising.
These findings suggest that exercise has potential neuroprotective and neurorestorative 
effects in PD, which may be associated with subsequent improvements in overall brain 
health, mood, and especially cognition,118 though the majority of this evidence in PD comes 
from animal studies and small pilot studies. Other mechanisms may be active for the effects 
of exercise on sleep, and potentially include body temperature elevation (to promote slow 
wave sleep), increased cytokine levels, heart rate variability (and associated improvements 
in vagal modulation and parasympathetic control), as well as increased BDNF activity and 
associated changes in mood.152,202,203 As sleep disruption is a core symptom of depression, 
and aerobic exercise improves depression, it is plausible that exercise may benefit sleep as a 
function of improved mood, or vice versa.202,204 It may also be important to consider the 
potential effects of aerobic exercise on cholinergic function, as demonstrated in non-PD 
animal studies.205 It is unknown whether these positive effects translate to persons with PD, 
but it warrants examination, given the association between cholinergic dysfunction and 
disturbances of sleep, mood, and cognition in PD.132,149 Ultimately, sleep benefits from 
exercise may result from some of the same or alternative mechanisms as those that 
positively affect mood and cognition.
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It is also important to consider potential mechanisms specific to resistance exercise in PD. 
Progressive resistance training in PD has yielded improvements in strength and motor 
symptoms, as well as cognition.19,125 Future research should more closely examine the 
effects of resistance training on non-motor symptoms in PD, especially cognition, which 
may relate to reduced levels of homocysteine and/or increased levels of insulin-like growth 
factor I.206 At the same time, resistance training may facilitate motor improvements via 
increased neural drive and central neural changes, such as cross-education and reduced 
agonist-antagonist coactivation.207 These mechanisms may be relevant for PD given the 
reduced muscle activation observed in the disorder, which largely contributes to 
bradykinesia and muscle weakness.206 Drawing from functional neuroimaging studies, 
resistance training may also promote functional neuroplasticity in the cortex and basal 
ganglia, although all of these potential mechanisms require further study in PD.206 For a 
review of potential mechanisms of resistance exercise in PD, please see 206.
Exercise Dose and Adherence in PD
Public health guidelines recommend a minimum of 150 minutes of moderate-intensity 
aerobic exercise plus 2–3 sessions of strengthening exercises per week for adults aged 18–
65,208 but it is unknown whether this recommendation is also appropriate for individuals 
with PD. Optimal dosing of exercise in PD has not been determined. Current research efforts 
are beginning to examine this question, including an ongoing multi-site, randomized, 
controlled study designed to compare moderate-intensity to high-intensity aerobic training in 
PD.209 Intensive rehabilitation strategies (three daily exercise sessions, 60 minutes each, 5 
days per week, for 4 weeks) that include aerobic exercise (heart rate reserve ≤60%; 
maximum speed of treadmill scrolling=3.5 km/hour) revealed increased BDNF levels and 
improved motor symptoms in the early stages of PD, suggesting the benefits of higher 
intensity exercise196 as well as potential benefits in cognition via BDNF. Other exercise 
trials in PD, however, reveal equivalent benefits related to physical function for both low 
(50 minutes at 40%-50% of heart rate reserve) and high (30 minutes at 70%-80% of heart 
rate reserve) intensity of aerobic exercise conducted 3 times a week for 3 months.79 In 
studies examining the benefits of strength training, high-intensity resistance programs have 
been shown to be safe and efficacious and associated with greater improvements in quality 
of life relative to active control groups.8,210,211 A progressive resistance training program (at 
least 5% increase in resistance as participants were able) was found to be more effective in 
improving motor symptoms than a strengthening program that was not progressive (no 
systematic increase in load), suggesting greater benefits of a high dosing,8 although both 
programs produced improvements in cognition after 24 months.125 The only other non-
motor outcome included in these studies was quality of life, which may capture secondary 
effects on mood, but otherwise, the effects of exercise intensity on mood and sleep in PD 
remain largely unknown and warrant further study.212
Generally speaking, adherence to exercise programs among adults with PD is relatively high 
(often >80%) in the context of research where there is typically a great deal of emphasis on 
promoting adherence.213 Likewise, across exercise trials in PD, retention rates are largely 
above 80%, with studies typically conducted in clinic and lasting 8 weeks on average, 
though some studies have reported similar retention rates for trials of a longer duration (up 
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to two years).8,79,213 Persons with PD tolerate exercise programs quite well with relatively 
low dropout rates (~10–20%) and minimal adverse effects.8,18,78,79,82,213,214 The majority 
of adverse events tend to consist of relatively mild musculoskeletal issues that resolve 
relatively quickly and do not require medical attention or restrict activities.18,82,214 This 
minimal-risk profile compares favorably to medications for non-motor symptoms in PD,215 
and provides further support for the use of exercise to simultaneously improve multiple 
motor and non-motor symptoms. At the same time, it should be noted that the largely 
supervised, in-clinic nature of current exercise studies in PD may limit generalizability of 
these findings to motivated research participants who have access to a highly structured 
research setting. Further research is warranted to better examine the longevity of effects and 
to effectively tailor the content, dose, and delivery of exercise programs to individuals at 
various stages of PD.
Treatment Stage and Exercise Intervention
Exercise has been shown to be beneficial to individuals with PD across Hoehn & Yahr 
stages I-IV, with most trials focusing on stages II and III.6,12,216–218 At the same time, the 
potential neuroprotective and neurorestorative effects of exercise118 underscore its 
importance early in the course of the disease.219 Non-motor symptoms of PD, including 
disturbances in sleep and mood, can emerge years before the motor symptoms.136,220,221 In 
particular, individuals in the early stages may present with depression or anxiety that may be 
more distressing or interfering than the motor symptoms.222 Accordingly, exercise programs 
are particularly well suited to early implementation in PD with the potential for diffuse non-
motor benefits (e.g. mood, sleep, cognition) and few side effects or adverse events. By 
implementing exercise interventions to improve depression, for example, in the early stages 
of PD, we can hope to also affect associated comorbidities, such as anxiety, memory 
difficulties, and sleep disruption223 and subsequently improve daily functioning and quality 
of life (e.g. 224). Of note, sufficient dopamine replenishment, most often with carbidopa/
levodopa, may be necessary to facilitate adherence and motivation for regular exercise and 
to avoid the formation of sedentary habits among individuals with PD.201,225 The majority 
of exercise trials in PD have been conducted with participants on appropriate dosages of 
dopaminergic medication, and the combined effect of dopaminergic medication plus 
exercise in PD has yielded greater physical benefits relative to medication or exercise 
alone.226 These findings highlight the importance of dopamine replenishment to enhance 
motor functioning and allow adults with PD to exercise at sufficient doses and intensities. In 
sum, for as long as individuals with PD are able to safely engage in physical activity, 
exercise should be seriously considered as an intervention strategy with the potential for 
widespread benefits for both non-motor and motor symptoms.
Conclusion
The conceptualization of PD has shifted from that of a pure motor disorder, with a 
burgeoning research effort in the domain of non-motor symptoms.4,36 There is as yet limited 
research on the management of mood, cognitive, and sleep symptoms in PD,34 with these 
symptoms often being comorbid.227 As we expand our understanding of the etiology and 
manifestation of the non-motor symptoms, a shift in attention to identifying and prescribing 
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effective treatment is warranted. If these symptoms do share underlying pathologies, it is 
possible that a single treatment may yield multi-faceted symptom improvement.
Aerobic and resistance exercise, in particular, offer especially promising treatment strategies 
for alleviating a spectrum of PD symptoms, including motor function, mood, cognition, and 
sleep. It is important to emphasize that exercise programs have generally been well tolerated 
in PD with few adverse events,12,216,228,229 attenuating concerns about the ability of 
individuals with PD to successfully complete prescribed exercise due to motor limitations.
In conclusion, exercise presents a particularly feasible treatment approach in PD with 
minimal side effects and the potential to yield broad-spectrum benefits related to mood, 
cognition, and sleep, particularly if implemented in the early stages of the disease. The 
known benefits of exercise in healthy older adults may very well translate to this population, 
driven by potentially overlapping mechanisms. As with the majority of PD studies, exercise 
research in PD has focused primarily on the motor symptoms and largely failed to consider 
its potential to improve non-motor symptoms. Future studies should include a variety of 
non-motor outcome measures to systematically examine the effects of exercise on these 
symptoms. With greater research and clinical attention devoted to the potential utility of 
exercise interventions in PD, we may meet the goal of simultaneously treating motor and 
non-motor symptoms, and ultimately optimize quality of life for persons living with this 
disorder.
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